Результаты поиска - Jeffrey V. Leyton

  • Отображение 1 - 6 результаты of 6
Отмена результатов
  1. 1
    Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?

    Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors? по Olga Bednova, Jeffrey V. Leyton

    Опубликовано 2020
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

    Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development по Manar Hammood, Andrew W. Craig, Jeffrey V. Leyton

    Опубликовано 2021
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

    Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats по Brent A. Williams, Arjun Law, Judit Hunyadkürti, Stéphanie Désilets, Jeffrey V. Leyton, Armand Keating

    Опубликовано 2019
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors

    Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors по Jeffrey V. Leyton, Tove Olafsen, Eric J. Lepin, Scott Hahm, Karl B. Bauer, Robert E. Reiter, Anna M. Wu

    Опубликовано 2008
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

    Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan по Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamäki, Jorma Isola, Jeffrey V. Leyton, Pirjo Laakkonen, Heikki Joensuu, Márk Barok

    Опубликовано 2025
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors

    An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors по Eric J. Lepin, Jeffrey V. Leyton, Yu Zhou, Tove Olafsen, Felix B. Salazar, Katelyn E. McCabe, Scott Hahm, James D. Marks, Robert E. Reiter, Anna M. Wu

    Опубликовано 2010
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: